su011248
Anaplastic Gliomas
Center Trials & TreatmentPhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Anaplastic Gliomas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Axitinib Center Trials & Treatment | Phase 1 | CC |
gw786034 Center Trials & Treatment | Phase 1 | CC |
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →